lipid nanoparticle

Dicerna's new RNAi triggers and conjugate technology are entirely proprietary and fall outside of intellectual property held by other organizations, according to a company official.

Arcturus Therapeutics this week announced new data showing that its proprietary lipid nanoparticles are capable of functionally delivering messenger RNA into the livers of mice, which a company official said opens the door for the use of the technology with CRISPR-based drugs.

Researchers from Tekmira Pharmaceuticals last week published new data showing that siRNAs targeting Marburg virus that have been formulated with the company's lipid nanoparticles could provide up to 100 percent post-exposure protection against infection in guinea pig models.

Alnylam Pharmaceuticals researchers last month published details on the company’s efforts to improve lipid nanoparticles for RNAi drug delivery.

Alnylam Pharmaceuticals last week scored a victory in its ongoing patent-infringement suit against partner Tekmira Pharmaceuticals after the US Federal Court hearing the case ruled that Alnylam does, as the exclusive sublicensee of the intellectual property at issue, have the rig

Marina Biotech said this week that it has signed an agreement giving DNA oligo drug firm ProNai Therapeutics the exclusive rights to its Smarticle delivery technology for DNA-based drug development.

Alnylam Pharmaceuticals this week said that the US Patent and Trademark Office has issued a notice of allowance for one of the company's patent applications related to lipid nanoparticles for systemic RNAi drug delivery.

Tekmira Pharmaceuticals this week announced that the US Patent and Trademark Office has declared a patent interference for Alnylam Pharmaceuticals' US patent covering siRNAs against a key target for its phase I liver cancer drug ALN-VSP.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.